Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting

Active, not recruitingOBSERVATIONAL
Enrollment

281

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

January 15, 2026

Study Completion Date

February 15, 2026

Conditions
AsthmaAsthma PatientsAsthma Bronchiale
Interventions
DRUG

BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg

As this is a non-interventional study, it is accordance with routing clinical practice. The assignment of patients to Trimbow 172/5/9 mcg should be made independently from the study.

Trial Locations (14)

Unknown

AIPSMCPP Dr. Elina Smilkova, Blagoevgrad

Medical Center Viva Phenix, Dobrich

Medical Center Hipocrat, Gabrovo

ASIMPIDPP Dr. Veselin Kalfov, Haskovo

Medical Center Denitza, Montana

IPASMC Dr. Kostadinka Sotirova, Pazardzhik

Group practice for specialized medical care - Asthma Center Pleven, Pleven

AIPSACA Dr. Talyat Cholak, Razgrad

AIPSMC Dr. Svetlan Mihaylov, Stara Zagora

Medical Center Third Policlinic, Stara Zagora

MHAT Svoge, Svoge

AIPSMCPP Dr. Nikolay Lichev V. Tarnovo, Veliko Tarnovo

Medical Center St. Ivan Rilski, Vidin

AIPSMCPP Dr. Bilyana Ivanova, Vratsa

All Listed Sponsors
lead

Chiesi Bulgaria

INDUSTRY

NCT06786767 - Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting | Biotech Hunter | Biotech Hunter